Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics entered into a private placement that closed on October 10, 2025, selling 175,000 shares of common stock and pre-funded warrants for up to 2,075,000 shares, together with Series F warrants for up to 4,500,000 shares. The combined price was $2.00 per share (or pre-funded warrant) plus accompanying Series F warrants to acquire two shares. The company received approximately $4.0 million in proceeds after fees.
Pre-funded warrants are immediately exercisable at $0.0001 per share and expire once exercised. Series F warrants are immediately exercisable at $1.75 per share and expire five and one-half years from issuance. The placement agent received warrants to purchase up to 180,000 shares, with an exercise price equal to 125% of the combined price per share and Series F warrants sold.
Bluejay agreed to register for resale the 175,000 shares and 6,755,000 warrant shares, file by October 24, 2025, and keep the registration effective until the registered shares may be sold under Rule 144. Issuances are restricted for 90 days after effectiveness, and certain variable-rate deals and splits are limited for one year. Warrant exercises are capped at 4.99% or 9.99% beneficial ownership, subject to notice-based adjustments.
Bluejay Diagnostics, Inc. entered into an amendment on October 3, 2025 to its existing Master Service Agreement and Master Supply Agreement with Sanyoseiko Co., Ltd.. The change is tied to Bluejay’s commercialization of its Symphony platform, a near-patient testing system designed to provide rapid results for biomarkers such as IL-6 used in sepsis management.
Under the amended arrangements, Sanyoseiko will provide end-to-end support for the Symphony platform. This includes supporting redevelopment of analyzers and cartridges with hardware, software, and design updates, managing raw material sourcing and vendor compliance, and acting as Bluejay’s contract manufacturer for analyzers, cartridges, and related components. Sanyoseiko will also handle fulfillment, kit assembly, labeling, packaging, shipping, and quality control, as well as regulatory and quality management support and equipment storage and maintenance. Bluejay also furnished a related press release as an exhibit.
Bluejay Diagnostics, Inc. entered into an amendment on October 3, 2025 to its existing Master Service Agreement and Master Supply Agreement with Sanyoseiko Co., Ltd.. The change is tied to Bluejay’s commercialization of its Symphony platform, a near-patient testing system designed to provide rapid results for biomarkers such as IL-6 used in sepsis management.
Under the amended arrangements, Sanyoseiko will provide end-to-end support for the Symphony platform. This includes supporting redevelopment of analyzers and cartridges with hardware, software, and design updates, managing raw material sourcing and vendor compliance, and acting as Bluejay’s contract manufacturer for analyzers, cartridges, and related components. Sanyoseiko will also handle fulfillment, kit assembly, labeling, packaging, shipping, and quality control, as well as regulatory and quality management support and equipment storage and maintenance. Bluejay also furnished a related press release as an exhibit.
Bluejay Diagnostics, Inc. reported that its Board of Directors updated leadership roles on the Board and its key committees, effective August 15, 2025. Donald R. Chase was appointed Chairperson of the Board, succeeding Douglas C. Wurth. Mr. Wurth became Chairperson of the Nominating and Corporate Governance Committee, succeeding Fred S. Zeidman, and Mr. Zeidman was named Chairperson of the Compensation Committee, succeeding Mr. Chase.
Mr. Chase continues to serve as Chairperson of the Audit Committee, and all three standing Board committees remain composed of Messrs. Chase, Wurth, and Zeidman. The Board describes these changes as part of its periodic review of governance assignments and notes that all three directors are considered independent under Nasdaq listing rules and Rule 10A-3 under the Securities Exchange Act of 1934.
Bluejay Diagnostics, Inc. furnished a Current Report stating that, following its quarterly report for the fiscal quarter ended June 30, 2025, the company issued a press release providing a 2025 second quarter business and corporate update.
The press release is furnished as Exhibit 99.1 and the cover page interactive data file is included as Exhibit 104. The filing specifies the information is being furnished and is not "filed" under the Exchange Act and will not be incorporated by reference into other filings unless identified. The report was signed by Neil Dey, President and Chief Executive Officer.